This slide deck, part of a two-part series, led by by Sarah A. Holstein, MD, PhD, and Ashley E. Rosko, MD, will explore expert perspectives on practice-changing developments in the management of multiple myeloma and will also include updates from the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition.
Part 2 will familiarize practitioners with indications of multiple myeloma progression and timing of therapy, highlight practice-changing trials in the early and late relapse settings, and discuss how approaches to relapsed/refractory multiple myeloma are changing based on emerging data.